1
|
Traspov AA, Minashkin MM, Poyarkov SV, Komarov AG, Shtinova IA, Speshilov GI, Karbyshev IA, Pozdniakova NV, Godkov MA. The rs17713054 and rs1800629 polymorphisms of genes LZTFL1 and TNF are associated with COVID-19 severity. BRSMU 2022. [DOI: 10.24075/brsmu.2022.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Both genetic and non-genetic factors are responsible for high interindividual variability in response to SARS-CoV-2. Despite the fact that multiple genetic polymorphisms have been identified as risk factors of severe COVID-19, such polymorphisms are still insufficiently studied in the Russian population. The study was aimed to identify genetic determinants associated with severe COVID-19 in the sample of patients from the Russian Federation. The correlation of the rs17713054 polymorphism in gene LZTFL1 and rs1800629 polymorphism in gene TNF (tumor necrosis factor) with the COVID-19 severity was assessed. DNA samples obtained from 713 patients (324 males and 389 females) aged 18‒95 with COVID-19 of varying severity were analyzed. The rs1800629 polymorphism of gene TNF (OR = 1.5; p = 0.02) and rs17713054 polymorphism of gene LZTFL1 (OR = 1.60; p = 0.0043) were identified as risk factors of severe disease. The TNF polymorphism rs1800629 and LZTFL1 polymorphism rs17713054 could be considered as potential predictive biomarkers. The rs17713054 G > A polymorphism was strongly associated with severe disease. In the future the findings may provide the basis for the development of test-systems for prediction of the risk of severe viral respiratory diseases.
Collapse
Affiliation(s)
| | | | | | - AG Komarov
- State Budget Institution Of Health Of The City Of Moscow "Diagnostic Center (Center For Laboratory Research) Of The Department Of Health Of The City Of Moscow" Russian Federation, , Moscow
| | - IA Shtinova
- State Budget Institution Of Health Of The City Of Moscow "Diagnostic Center (Center For Laboratory Research) Of The Department Of Health Of The City Of Moscow" Russian Federation, , Moscow
| | - GI Speshilov
- State Budget Institution Of Health Of The City Of Moscow "Diagnostic Center (Center For Laboratory Research) Of The Department Of Health Of The City Of Moscow" Russian Federation, , Moscow
| | - IA Karbyshev
- State Budget Institution Of Health Of The City Of Moscow "Diagnostic Center (Center For Laboratory Research) Of The Department Of Health Of The City Of Moscow" Russian Federation, , Moscow
| | | | - MA Godkov
- Sklifosovsky Research Institute for Emergency Medicine, Moscow, Russia
| |
Collapse
|
2
|
Shkurnikov MY, Averinskaya DA, Komarov AG, Karbyshev IA, Speshilov GI, Shtinova IA, Doroshenko DA, Vechorko VI, Drapkina OM. Association of HLA Class I Genotype with Mortality in Patients with Diabetes Mellitus and COVID-19. DOKL BIOCHEM BIOPHYS 2022; 507:289-293. [PMID: 36786988 PMCID: PMC9926432 DOI: 10.1134/s1607672922060114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Revised: 08/31/2022] [Accepted: 09/02/2022] [Indexed: 02/15/2023]
Abstract
Numerous studies showed that diabetes mellitus (DM) increases the risk of death from COVID-19 by five times. It is generally accepted that the high lethality of COVID-19 against the background of DM is due to the main complications of this disease: micro- and macroangiopathies, as well as heart and kidney failure. In addition, it was shown that acute respiratory viral infection increases the production of interferon gamma, increases muscle resistance to insulin, and modulates the activity of effector CD8+ T cells. The ability of CD8+ T cells to recognize SARS-CoV-2-infected cells depends not only on humoral factors but also on individual genetic characteristics, including the individual set of major histocompatibility complex class I (MHC-I) molecules. In this study, the relationship of the MHC-I genotype of patients with DM aged less than 60 years with the outcome of COVID-19 was studied using a sample of 222 patients. It was shown that lethal outcomes of COVID-19 in patients with DM are associated with the low affinity of the interaction of an individual set of MHC-I molecules with SARS-CoV-2 peptides.
Collapse
Affiliation(s)
- M. Yu. Shkurnikov
- Faculty of Biology and Biotechnology, HSE University, Moscow, Russia ,Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - D. A. Averinskaya
- Faculty of Biology and Biotechnology, HSE University, Moscow, Russia
| | - A. G. Komarov
- Moscow City Public Institution of Health Care Diagnostic Center (Laboratory Testing Center) of Moscow Health Department, Moscow, Russia
| | - I. A. Karbyshev
- Moscow City Public Institution of Health Care Diagnostic Center (Laboratory Testing Center) of Moscow Health Department, Moscow, Russia
| | - G. I. Speshilov
- Moscow City Public Institution of Health Care Diagnostic Center (Laboratory Testing Center) of Moscow Health Department, Moscow, Russia
| | - I. A. Shtinova
- Moscow City Public Institution of Health Care Diagnostic Center (Laboratory Testing Center) of Moscow Health Department, Moscow, Russia
| | - D. A. Doroshenko
- Moscow City Public Institution of Health Care Filatov City Clinical Hospital of Moscow Health Department, Moscow, Russia
| | - V. I. Vechorko
- Moscow City Public Institution of Health Care Filatov City Clinical Hospital of Moscow Health Department, Moscow, Russia
| | - O. M. Drapkina
- National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
| |
Collapse
|
3
|
Shkurnikov MY, Averinskaya DA, Komarov AG, Karbyshev IA, Speshilov GI, Shtinova IA, Doroshenko DA, Vechorko VI. Relationship of Covid-19 Severity with SARS-CoV-2 NS8 Protein Mutations Depending on Virus Strain. DOKL BIOCHEM BIOPHYS 2022; 507:242-246. [PMID: 36786981 PMCID: PMC9926417 DOI: 10.1134/s1607672922060102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Revised: 08/14/2022] [Accepted: 08/16/2022] [Indexed: 02/15/2023]
Abstract
In mid-2021, the Delta strain of SARS-CoV-2 caused the third wave of the COVID-19 pandemic. Huge efforts have been devoted to studying the effect of its mutations on the effectiveness of neutralizing antibodies. Much less attention was paid to the individual features of the presentation of its peptides by molecules of the major histocompatibility complex class I (MCHC-I). In this study, the correlation of the HLA-I genotype of patients under the age of 60 years with the severity of COVID-19 caused by the two most common variants of the SARS-CoV-2 Delta strain in the summer of 2021: AY.122 and B.1.617.2 was studied. Analysis of the severity of the course of COVID-19 revealed a more severe course of the disease caused by the AY.122 variant. Comparison of the mutation profile of the two most common variants of the Delta strain showed that that the G8R mutation in the NS8 protein makes the greatest contribution to the ability of MHC-I to present viral peptides. Given that the NS8 protein is able to suppress the maturation of MHC-I molecules, the appearance of a mutation in one of its immunogenic epitopes could make a significant contribution to the prevalence of the AY.122 variant in the Russian population.
Collapse
Affiliation(s)
- M. Yu. Shkurnikov
- Faculty of Biology and Biotechnology, HSE University, Moscow, Russia ,Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - D. A. Averinskaya
- Faculty of Biology and Biotechnology, HSE University, Moscow, Russia
| | - A. G. Komarov
- Moscow City Public Institution of Health Care Diagnostic Center (Laboratory Testing Center) of Moscow Health Department, Moscow, Russia
| | - I. A. Karbyshev
- Moscow City Public Institution of Health Care Diagnostic Center (Laboratory Testing Center) of Moscow Health Department, Moscow, Russia
| | - G. I. Speshilov
- Moscow City Public Institution of Health Care Diagnostic Center (Laboratory Testing Center) of Moscow Health Department, Moscow, Russia
| | - I. A. Shtinova
- Moscow City Public Institution of Health Care Diagnostic Center (Laboratory Testing Center) of Moscow Health Department, Moscow, Russia
| | - D. A. Doroshenko
- Moscow City Public Institution of Health Care Filatov City Clinical Hospital of Moscow Health Department, Moscow, Russia
| | - V. I. Vechorko
- Moscow City Public Institution of Health Care Filatov City Clinical Hospital of Moscow Health Department, Moscow, Russia
| |
Collapse
|
4
|
Petrikov AS, Shoĭkhet IN, Dudin DV, Karbyshev IA. [Use of a thrombin inhibitor for treatment of deep vein thrombosis and pulmonary thromboembolism in patients with thrombophilia]. Angiol Sosud Khir 2017; 23:33-40. [PMID: 28594794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Presented herein are the results of oral administration of dabigatran etexilate for treatment and secondary prevention of lower-limb deep vein thrombosis (DVT) and pulmonary thromboembolism (PTE) in patients with established thrombophilia, studying its efficacy and safety in prolonged administration during a year as compared with warfarin. The study group included a total of fifty-seven 18-to-79-year-old patients (33 men and 24 women) with DVT and PTE, taking dabigatran etexilate. The comparison group was composed of a total of 126 patients (65 men and 61 women) with DVT and PTE, taking warfarin. Efficacy of the drugs was analysed in relation to the development of relapses thromboembolic complications, with the drugs' safety profile being evaluated in relation to the development of major and clinically significant haemorrhage. It was determined that prolonged administration of dabigatran etexilate taken at a fixed dose (150 mg twice daily) for 6-12 months in patients with DVT and PTE and with confirmed thrombophilia turned out to be effective for secondary prevention of relapsing venous thromboembolic complications and lethal outcomes, indirectly contributing to recanalization of the lower-limb venous bed, with the drug possessing a favourable profile of safety concerning the development of haemorrhagic complications as compared with warfarin and requiring no routine laboratory monitoring.
Collapse
Affiliation(s)
- A S Petrikov
- Chair of Faculty Surgery named after Professor I.I. Neimark with the Course of Surgery of the Faculty of Advanced Medical Training and Professional Retraining of Specialists, Altai State Medical University of the RF Public Health Ministry, Barnaul, Russia; Department of Vascular Surgery, Municipal Hospital No5, Barnaul, Russia; Division of Laboratory Diagnosis, Diagnostic Centre of the Altai Territory, Barnaul, Russia
| | - Ia N Shoĭkhet
- Chair of Faculty Surgery named after Professor I.I. Neimark with the Course of Surgery of the Faculty of Advanced Medical Training and Professional Retraining of Specialists, Altai State Medical University of the RF Public Health Ministry, Barnaul, Russia; Department of Vascular Surgery, Municipal Hospital No5, Barnaul, Russia
| | - D V Dudin
- Chair of Faculty Surgery named after Professor I.I. Neimark with the Course of Surgery of the Faculty of Advanced Medical Training and Professional Retraining of Specialists, Altai State Medical University of the RF Public Health Ministry, Barnaul, Russia; Department of Vascular Surgery, Municipal Hospital No5, Barnaul, Russia
| | - I A Karbyshev
- Division of Laboratory Diagnosis, Diagnostic Centre of the Altai Territory, Barnaul, Russia
| |
Collapse
|
5
|
Chuchalin AG, Tseimakh IY, Momot AR, Mamaev AN, Karbyshev IA, Strozenko LA. [THROMBOGENIC RISK FACTORS IN PATIENTS WITH EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE]. Klin Med (Mosk) 2015; 93:18-23. [PMID: 27149808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
We studied activation of hemostatic reactions together with mechanisms of systemic inflammation and genetic factors responsible for thrombogenic risk in 65 patients suffering exacerbation of chronic obstructive pulmonary disease with 2 or 3 positive criteria proposed by N.Anthonisen at al. (1987). The levels of indicators of systemic inflammation, such as C-reactive protein and tumour necrosis factor-alpha, increased concurrently with those of homocysteine, endothelin-1, Willebrand factor plasminogen activator inhibitor type 1, and thrombin-antithrombin complex (marker of thrombinemia). The prevalence of pathological alleles ofprotein genes involved in the hemostasis system and folate cycle remained as in the control group. A relationship between plasma levels of thrombin-antithrombin complex and Willebrand factor and the activity of indicators of systemic inflammation was documented. Treatment of exacerbation resulted in the decrease in the levels of the thrombin- antithrombin complex, inhibitor of the extrinsic pathway of coagulation, and plasminogen activator inhibitor type 1. The treatment failed to normalize parameters of thrombinemia and blood fibrinolytic potential.
Collapse
|
6
|
Petrikov AS, Shoikhet YN, Vyatkin DA, Zakharchenko KK, Karbyshev IA. [Use of dabigatran etexilate for treatment of deep vein thrombosis and pulmonary artery thromboembolism]. Angiol Sosud Khir 2015; 21:27-37. [PMID: 26035562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The authors present herein their experience in oral administration of dabigatran etexilate for treatment of lower-limb deep vein thrombosis and pulmonary thromboembolism in patients with thrombophilia, as well as assessment of its efficacy and safety. The study included a total of nineteen 20-to-79-year-old patients (11 men and 8 women) with venous thromboembolic complications. An inclusion criterion was the presence of lower-limb deep vein thrombosis documented in the B-mode in ultrasonography alone or in a combination with pulmonary thromboembolism confirmed by angiopulmonography end echocardiography. The exclusion criteria were as follow: oncological diseases, a history of surgical interventions, acute infections, skeletal injuries and fractures, long-term immobilization, age under 20 and over 79 years. For 6 months the authors evaluated patients' tolerance of dabigatran, its efficacy, as well as the profile of safety concerning the development of major and clinically significant haemorrhage. It was determined that administration of dabigatran in patients with confirmed thrombophilia at a fixed dose (150 mg twice daily) during 6 months for treatment of lower-limb venous thromboses and pulmonary thromboembolism turned out to be effective and safe, with the drug possessing a good profile of safety and its administration requiring no routine laboratory monitoring.
Collapse
Affiliation(s)
- A S Petrikov
- Chair of Faculty Surgery named after Professor I.I. Neimark with the Course of Surgery of the Faculty of Advanced Medical Training and Professional Retraining of Specialists, Altai State Medical University of the RF Public Health Ministry, Barnaul, Russia; Department of Vascular Surgery, Municipal Hospital No5, Barnaul, Russia; Department of Laboratory Diagnosis, Diagnostic Centre of the Altai Territory, Barnaul, Russia
| | - Ya N Shoikhet
- Chair of Faculty Surgery named after Professor I.I. Neimark with the Course of Surgery of the Faculty of Advanced Medical Training and Professional Retraining of Specialists, Altai State Medical University of the RF Public Health Ministry, Barnaul, Russia; Department of Vascular Surgery, Municipal Hospital No5, Barnaul, Russia
| | - D A Vyatkin
- Department of Vascular Surgery, Municipal Hospital No5, Barnaul, Russia
| | - K K Zakharchenko
- Department of Vascular Surgery, Municipal Hospital No5, Barnaul, Russia
| | - I A Karbyshev
- Department of Laboratory Diagnosis, Diagnostic Centre of the Altai Territory, Barnaul, Russia
| |
Collapse
|
7
|
Chuchalin AG, Tseymakh IY, Momot AP, Mamaev AN, Karbyshev IA, Kostyuchenko GI. Changes in systemic inflammatory and hemostatic response in patients with co-morbidity of exacerbation of chronic obstructive pulmonary disease, chronic heart failure and obesity. ACTA ACUST UNITED AC 2014. [DOI: 10.18093/0869-0189-2014-0-6-25-32] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|